Pennsylvania-based Frontage Laboratories has picked up Canadian CRO Nucro-Technics for an undisclosed price.
The deal will give Frontage an expanded clinical trial footprint in North America in addition to its presence in China, according to an Aug. 15 press release.
Nucro-Technics, which is based in a 60,000-square-foot facility in Toronto, conducts analytical chemistry, microbiology, toxicology, bioanalytical and stability sample storage and testing services. The CRO also offers consulting services.
“This acquisition not only significantly strengthens our presence in Canada, but also will enable the combined organization to offer a more expansive suite of services to clients across the globe,” Frontage’s CEO Abdul Mutlib, Ph.D., said in the release.
In late December, Frontage announced it had partnered with Eisai and Biogen to support the PK and PD biomarker bioanalysis of the two companies' now FDA-approved Alzheimer’s therapy Leqembi as part of the investigational global phase 3 study in the U.S. and China.